Top Story

MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).
Womens Imaging
CEM on par with MRI for breast cancer diagnosis, local staging
CEM alone in a prospective study achieved perfect sensitivity and negative predictive value in diagnosing breast cancer.
Featured
Cancer Target
Molecular Imaging
New PET tracer show promise in neuroblastoma
Who's paying, and for what, is the question that actually decides whether AI in healthcare gets funded.
AI
The cost of AI, and finding its breakeven point
Latest News
Experts at the Royal College of Radiologists’ 2nd Annual Global AI Conference discussed how AI could help move cancer care toward more personalized treatment, from targeted radionuclide therapy dosing to drug discovery.
AI aims to decode targeted radiotherapy response
July 8, 2026
Dr. Rowland Illing, chief medical officer at Amazon Web Services (AWS) and a former interventional radiologist.
RCR: Agentic AI is off the leash, and already a workhorse for health systems
July 7, 2026
European Parliament, Brussels. Policymakers, clinicians, and patient representatives at the 'Imaging Saves Lives' event, July 2.
99% wasn't enough: How persistence in imaging changes the picture
July 6, 2026
A visual abstract of the study.
PET/MRI can reduce the need for biopsies in prostate cancer
July 2, 2026
Cases of the Week
Check out our Cases of the Week!
39-year-old man with orbital proptosis, possible orbital mass revisited
A 39-year-old man presented with left orbital proptosis and concern for an orbital mass.
40-year-old man with right hip finding revisited
22-year-old woman with neck swelling revisited
View All Cases
MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).
Womens Imaging
CEM on par with MRI for breast cancer diagnosis, local staging
Molecular Imaging
New PET tracer show promise in neuroblastoma
CT
99% wasn't enough: How persistence in imaging changes the picture
Molecular Imaging
PET/MRI can reduce the need for biopsies in prostate cancer
CT
Imaging takes center stage in Europe's Safe Hearts Plan
Who's paying, and for what, is the question that actually decides whether AI in healthcare gets funded.
AI
The cost of AI, and finding its breakeven point
AI
AI aims to decode targeted radiotherapy response
AI
RCR: Agentic AI is off the leash, and already a workhorse for health systems
AI
Most patients want to know if AI being used for imaging reports
AI
More work than relief: AI in the wrong seat, RCR census finds
Blue Earth Therapeutics Logo
Industry News
Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial
Industry News
Philips launches new ultrasound system
Industry News
Imagion extends collaboration with Siemens on MRI contrast agent
CT
Median gets CE marking for lung cancer screening software
Womens Imaging
Quibim launches AI breast MRI tool across Europe, UK
More from AuntMinnieEurope
Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial
By AuntMinnie.com staff writers
The study is evaluating an investigational alpha-emitting PSMA-targeted radiopharmaceutical in prostate cancer patients.
July 9, 2026
Blue Earth Therapeutics Logo
Philips launches new ultrasound system
By AuntMinnie.com staff writers
The system features AI-powered workflows and is designed for high-volume clinical environments.
July 8, 2026
Alturion
Imagion extends collaboration with Siemens on MRI contrast agent
By AuntMinnie.com staff writers
Siemens will provide in-kind expertise and technical support to clinical sites.
July 8, 2026
Ai Handshake
Median gets CE marking for lung cancer screening software
By AuntMinnie.com staff writers
The CE marking follows the U.S. Food and Drug Administration (FDA)'s 510(k) clearance of eyonis LCS in February.
July 6, 2026
Lung Cancer
Quibim launches AI breast MRI tool across Europe, UK
By AuntMinnieEurope.com staff writers
The tool, QP-Breast, highlights suspicious areas on MRI and generates reports from imaging findings.
July 2, 2026
Qp Breast Press 02
Imaging takes center stage in Europe's Safe Hearts Plan
By Claudia Tschabuschnig
Radiology and nuclear medicine are poised to play a central role in implementing the European Commission's Safe Hearts Plan, speakers said during a joint ESR/EANM event in Brussels.
July 2, 2026
The Safe Hearts Plan aims to shift healthcare systems toward prevention, earlier diagnosis, and more personalized care.
GE HealthCare, University Hospital Essen open nuclear medicine center
By AuntMinnieEurope.com staff writers
The center features the first installation of GE HealthCare's StarGuide GX SPECT/CT scanner.
July 1, 2026
Ge
Can side-chain chemistry help radiologists choose a safer contrast agent after a hypersensitivity reaction?
By Claudia Tschabuschnig
Choosing an alternative contrast agent after an allergic reaction often falls to clinical judgment. A new review examines whether side-chain chemistry can make that decision a little more evidence based.
July 1, 2026
Dr. Aart J. van der Molen, of Leiden University Medical Center in Leiden, the Netherlands, is the lead author of a review exploring side-chain chemistry as a guide for selecting alternative iodine-based contrast media.
Most patients want to know if AI being used for imaging reports
By Amerigo Allegretto
Most patients want disclosure about whether AI is being used for their imaging reports.
June 30, 2026
Patient Cancer Doctor 400 (1)
Low muscle density on coronary CT linked to heart risk
By Will Morton
Patients with skeletal muscle attenuation below the median had a higher risk of mortality and myocardial infarction.
June 30, 2026
An example of machine learning–based multiorgan body composition assessment (TotalSegmentator V2.0.4, 1.5-mm high-resolution model) in a 63-year-old man with obstructive coronary artery disease and a skeletal muscle attenuation below the median. (A) Transverse, (B) coronal, and (C) sagittal CT images and curved planar reformations of the (D) left, (E) circumflex, and (F) right coronary arteries.
Medneo acquires Ramsay Diagnostics UK mobile imaging fleet
By AuntMinnieEurope.com staff writers
Medneo is acquiring Ramsay Diagnostics UK's mobile MRI and CT fleet and a six-year contract to provide mobile imaging services.
June 30, 2026
Mri Scanner2 400
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400